Kwang Dong Pharmaceutical Co., Ltd. (009290.KS)
KRW 5670.0
(0.0%)
KRW 5670.0
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 54.97 Billion KRW | -4.66% |
| 2022 | 54.51 Billion KRW | -11.24% |
| 2021 | 51.02 Billion KRW | -9.95% |
| 2020 | 85.19 Billion KRW | 8.97% |
| 2019 | 58.72 Billion KRW | 19.8% |
| 2018 | 51.59 Billion KRW | 6.1% |
| 2017 | 51.09 Billion KRW | -12.37% |
| 2016 | 57.3 Billion KRW | -7.11% |
| 2015 | 62.39 Billion KRW | 8.49% |
| 2014 | 58.05 Billion KRW | 10.42% |
| 2013 | 51.97 Billion KRW | 12.98% |
| 2012 | 46.28 Billion KRW | -5.9% |
| 2011 | 47.92 Billion KRW | 7.85% |
| 2010 | 44.9 Billion KRW | 11.54% |
| 2009 | 41.93 Billion KRW | -7.16% |
| 2008 | 42.51 Billion KRW | 6.24% |
| 2007 | 41.74 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 5.04 Billion KRW | -73.14% |
| 2024 Q1 | 20.84 Billion KRW | 112.34% |
| 2023 FY | - KRW | -4.66% |
| 2023 Q4 | 6.16 Billion KRW | -92.06% |
| 2023 Q3 | 77.69 Billion KRW | 0.8% |
| 2023 Q2 | 77.07 Billion KRW | 5.42% |
| 2023 Q1 | 73.11 Billion KRW | 460.47% |
| 2022 Q1 | 13.32 Billion KRW | -19.28% |
| 2022 Q2 | 15.45 Billion KRW | 15.99% |
| 2022 FY | - KRW | -11.24% |
| 2022 Q3 | 14.93 Billion KRW | -3.33% |
| 2022 Q4 | 13.04 Billion KRW | -12.68% |
| 2021 Q3 | 20.61 Billion KRW | 56.84% |
| 2021 Q1 | 13.67 Billion KRW | 9.23% |
| 2021 Q2 | 13.14 Billion KRW | -3.89% |
| 2021 FY | - KRW | -9.95% |
| 2021 Q4 | 16.5 Billion KRW | -19.95% |
| 2020 Q2 | 22.42 Billion KRW | 24.84% |
| 2020 Q3 | 18.1 Billion KRW | -19.28% |
| 2020 Q1 | 17.96 Billion KRW | 56.45% |
| 2020 FY | - KRW | 8.97% |
| 2020 Q4 | 12.52 Billion KRW | -30.82% |
| 2019 Q1 | 18.22 Billion KRW | 51.86% |
| 2019 Q3 | 15.34 Billion KRW | -23.9% |
| 2019 FY | - KRW | 19.8% |
| 2019 Q4 | 11.48 Billion KRW | -25.15% |
| 2019 Q2 | 20.15 Billion KRW | 10.61% |
| 2018 Q2 | 10.79 Billion KRW | -26.5% |
| 2018 Q3 | 16.91 Billion KRW | 56.69% |
| 2018 Q4 | 11.99 Billion KRW | -29.06% |
| 2018 FY | - KRW | 6.1% |
| 2018 Q1 | 14.68 Billion KRW | 30.89% |
| 2017 Q1 | 13.6 Billion KRW | 56.1% |
| 2017 Q4 | 11.22 Billion KRW | -32.19% |
| 2017 Q3 | 16.54 Billion KRW | 67.28% |
| 2017 FY | - KRW | -12.37% |
| 2017 Q2 | 9.89 Billion KRW | -27.31% |
| 2016 Q2 | 17.96 Billion KRW | 16.95% |
| 2016 Q3 | 16.46 Billion KRW | -8.39% |
| 2016 Q4 | 8.71 Billion KRW | -47.04% |
| 2016 FY | - KRW | -7.11% |
| 2016 Q1 | 15.36 Billion KRW | 19.54% |
| 2015 Q4 | 12.85 Billion KRW | -30.46% |
| 2015 FY | - KRW | 8.49% |
| 2015 Q3 | 18.48 Billion KRW | -0.38% |
| 2015 Q2 | 18.54 Billion KRW | 41.53% |
| 2015 Q1 | 13.1 Billion KRW | 7.21% |
| 2014 Q3 | 17.1 Billion KRW | 5.74% |
| 2014 Q2 | 16.17 Billion KRW | 34.43% |
| 2014 FY | - KRW | 10.42% |
| 2014 Q1 | 12.02 Billion KRW | -4.9% |
| 2014 Q4 | 12.22 Billion KRW | -28.52% |
| 2013 Q3 | 16.71 Billion KRW | 26.23% |
| 2013 Q4 | 12.64 Billion KRW | -24.33% |
| 2013 FY | - KRW | 12.98% |
| 2013 Q1 | 10.42 Billion KRW | -6.4% |
| 2013 Q2 | 13.24 Billion KRW | 27.01% |
| 2012 Q2 | 10.47 Billion KRW | 11.7% |
| 2012 Q3 | 12.58 Billion KRW | 20.08% |
| 2012 Q4 | 11.14 Billion KRW | -11.47% |
| 2012 FY | - KRW | -5.9% |
| 2012 Q1 | 9.38 Billion KRW | 0.0% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 Q2 | 13.15 Billion KRW | 31.87% |
| 2011 Q3 | 11.11 Billion KRW | -15.47% |
| 2011 Q1 | 9.97 Billion KRW | -7.36% |
| 2011 FY | - KRW | 7.85% |
| 2010 Q3 | 14.59 Billion KRW | 22.89% |
| 2010 Q2 | 11.87 Billion KRW | 37.75% |
| 2010 Q1 | 8.62 Billion KRW | -5.04% |
| 2010 Q4 | 10.76 Billion KRW | -26.24% |
| 2010 FY | - KRW | 11.54% |
| 2009 FY | - KRW | -7.16% |
| 2009 Q4 | 9.07 Billion KRW | -32.7% |
| 2009 Q3 | 13.49 Billion KRW | 46.81% |
| 2009 Q1 | 9.35 Billion KRW | -2.37% |
| 2009 Q2 | 9.18 Billion KRW | -1.77% |
| 2008 Q3 | 15.12 Billion KRW | 53.5% |
| 2008 Q2 | 9.85 Billion KRW | 1.33% |
| 2008 FY | - KRW | 6.24% |
| 2008 Q4 | 9.58 Billion KRW | -36.64% |
| 2008 Q1 | 9.72 Billion KRW | 5.2% |
| 2007 Q4 | 9.24 Billion KRW | -33.97% |
| 2007 Q2 | 10.8 Billion KRW | 41.42% |
| 2007 Q1 | 7.63 Billion KRW | 0.0% |
| 2007 FY | - KRW | 0.0% |
| 2007 Q3 | 13.99 Billion KRW | 29.56% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -1031.52% |
| Dong-A Socio Holdings Co., Ltd. | 141.36 Billion KRW | 61.112% |
| Ildong Holdings Co., Ltd. | -64.03 Billion KRW | 185.847% |
| HANDOK Inc. | 35.06 Billion KRW | -56.767% |
| Kukje Pharma Co., Ltd. | -1.03 Billion KRW | 5403.335% |
| Yuhan Corporation | 127.43 Billion KRW | 56.861% |
| Dong-A ST Co., Ltd. | 37.52 Billion KRW | -46.512% |
| SAMSUNG PHARM. Co., LTD. | -21.68 Billion KRW | 353.477% |
| Hanmi Pharm. Co., Ltd. | 323.33 Billion KRW | 82.998% |
| Hanall Biopharma Co.,Ltd | 4.99 Billion KRW | -1001.593% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | -263.621% |
| Dong Sung Bio Pharm.Co.,Ltd. | 3.42 Billion KRW | -1506.941% |
| MYUNGMOON Pharm co.,Ltd | 4.52 Billion KRW | -1114.498% |
| Hana Pharm Co., Ltd. | 35.48 Billion KRW | -54.913% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -1031.52% |
| Ilsung Pharmaceuticals Co., Ltd. | -18.47 Billion KRW | 397.605% |
| REYON Pharmaceutical Co., Ltd. | 6.55 Billion KRW | -738.648% |
| Aprogen pharmaceuticals,Inc. | -49.29 Billion KRW | 211.526% |
| JW Holdings Corporation | 187.88 Billion KRW | 70.741% |
| Ildong Pharmaceutical Co., Ltd. | -51.22 Billion KRW | 207.309% |
| Chong Kun Dang Pharmaceutical Corp. | 283.62 Billion KRW | 80.618% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 38.385% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 248.308% |
| Hyundai Pharmaceutical Co., Ltd. | 13.2 Billion KRW | -316.16% |
| Samil Pharmaceutical Co.,Ltd | 11.82 Billion KRW | -364.776% |
| Jeil Pharmaceutical Co.,Ltd | 18.65 Billion KRW | -194.685% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -1031.52% |
| Daewoong pharmaceutical Co.,Ltd | 164.91 Billion KRW | 66.665% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 38.385% |
| Yuhan Corporation | 127.43 Billion KRW | 56.861% |
| Jeil Pharma Holdings Inc | 33.47 Billion KRW | -64.217% |
| Yungjin Pharm. Co., Ltd. | 7.64 Billion KRW | -618.618% |
| Suheung Co., Ltd. | 77.02 Billion KRW | 28.633% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 38.385% |
| Samjin Pharmaceuticals Co., Ltd. | 36.63 Billion KRW | -50.058% |
| Korea United Pharm Inc. | 70.78 Billion KRW | 22.333% |
| CKD Bio Corp. | -1.63 Billion KRW | 3471.663% |
| Daewon Pharmaceutical Co., Ltd. | 49.79 Billion KRW | -10.403% |
| Dongwha Pharm.Co.,Ltd | 32.56 Billion KRW | -68.829% |
| Whan In Pharm Co.,Ltd. | 36.81 Billion KRW | -49.341% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 248.308% |
| Chong Kun Dang Holdings Corp. | 62.28 Billion KRW | 11.738% |
| Boryung Corporation | 114.28 Billion KRW | 51.9% |
| Bukwang Pharmaceutical Co., Ltd. | -30.56 Billion KRW | 279.837% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | -263.621% |
| JW Lifescience Corporation | 50.82 Billion KRW | -8.153% |